The standard's core principle is that the retesting of commercially prepared microbiological culture media is unnecessary for those media that have demonstrated proven reliability. The categorization of media that do not require retesting by the user is based on quality control data collected from surveys of clinical laboratories enrolled in the bacteriology proficiency-testing program conducted by the College of American Pathologists (CAP). These media types are well established for the recovery of clinically significant microorganisms. The standard applies to all commercial media listed in Table 2 of the document, regardless of packaging, plate, or tube design.
Its primary goal is to streamline laboratory operations by identifying "exempt" media—media with such a high track record of reliability that user retesting is considered unnecessary. Key updates in the A3 revision include: Expanded Exempt List
Given the regulatory shift away from M22-A3 in the U.S., you may be better served by seeking out more current and directly applicable resources. clsi m22a3 pdf free
Standardized protocols for checking pH, sterility, growth performance, and selective/inhibitory properties of the media. Why Laboratories Need CLSI M22-A3 Compliance
Please note that I couldn't find a direct link to a free PDF version of the document. If you're affiliated with an institution that has a subscription to CLSI guidelines, you may be able to access it through their library or online portal. The standard's core principle is that the retesting
However, it is critical to note that as of January 2016, the Centers for Medicare & Medicaid Services (CMS) no longer recognizes the categories of "exempt" and "nonexempt" media for quality control purposes under CLIA regulations. Instead, US laboratories subject to CLIA must develop an Individualized Quality Control Plan (IQCP) for applicable media or follow CLIA quality assurance regulations directly. Consequently, . The guidance in M22-A3 does not replace the need for an IQCP. Nevertheless, the standard remains technically valid and applicable to international laboratories, and it is still being retained in CLSI's library due to its value to the laboratory community.
While CLSI M22-A3 remains a landmark document in the history of laboratory microbiology, laboratory professionals should be aware of the evolution of these standards. The standard applies to all commercial media listed
Learn about the transition from M22-A3 to modern risk assessment models in the ASM Clinical Microbiology IQCP Guide
Websites offering premium medical and scientific documents for free are notorious breeding grounds for malware, ransomware, and phishing schemes. Clicking "Download PDF" on an unauthorized site can compromise your institution’s entire IT network—a catastrophic event for healthcare facilities bound by strict data privacy laws. 3. Accreditation Failures and Legal Risks
Before this standard, laboratories were often required to test every single batch of every type of agar or broth they received. M22-A3 significantly reduced this burden by categorizing many common media (like Blood Agar or MacConkey Agar) as "exempt" from routine user QC, provided the manufacturer provides a certificate of compliance. This saves laboratories significant time and resources while maintaining patient safety. specific culture media
Compliance with CLSI standards is not just a best practice; it is frequently a mandatory requirement for laboratory accreditation. Organizations like the College of American Pathologists (CAP), the Joint Commission, and national regulatory bodies (such as CMS under CLIA in the United States) align their inspection checklists with CLSI guidelines. By implementing CLSI M22-A3, laboratories can: